Ken Griffin Avadel Pharmaceuticals PLC Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$12.55 - $17.22 $769,315 - $1.06 Million	61,300 Added 32.92%	247,500 $4.18 Million
Q4 2023 Feb 14, 2024	BUY	$9.64 - $14.59 $97,364 - $147,359	10,100 Added 5.74%	186,200 $2.63 Million
Q3 2023 Nov 14, 2023	SELL	$10.3 - $15.99 $779,710 - $1.21 Million	-75,700 Reduced 30.06%	176,100 $1.81 Million
Q2 2023 Aug 14, 2023	SELL	$8.48 - $16.48 $359,552 - $698,752	-42,400 Reduced 14.41%	251,800 $4.15 Million
Q1 2023 May 15, 2023	SELL	$6.41 - $9.95 $2.73 Million - $4.23 Million	-425,300 Reduced 59.11%	294,200 $2.69 Million
Q4 2022 Feb 14, 2023	SELL	$5.02 - $10.0 $128,511 - $256,000	-25,600 Reduced 3.44%	719,500 $5.15 Million
Q3 2022 Nov 14, 2022	BUY	$2.57 - $7.31 $240,294 - $683,485	93,500 Added 14.35%	745,100 $3.73 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.